Infective Complications and Early Survival Outcomes with Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) in patients with Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study (ESMO-IO 2026) - Oct 25, 2026 - Abstract #227eP; Pres time: Dec 14, 2026; Location: Churchill Room; No abstract available
Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|